Introduction to Antiretroviral Drugs
Anti-retroviral drugs are medications which are mainly used for the treatment of HIV. This virus ‘Retrovirus’ is a cluster of viruses that belongs to the family of Retroviridae and holds their blueprint in the form of ribonucleic acid. As currently there is no cure of this disease, anti-retroviral drugs help in holding back the multiplication of these viruses rather than killing them.
Market size and Forecast
The global anti- retroviral drugs market is anticipated to grow on account of the growing frequency of HIV/AIDS cases. According to the World Health Organization, in 2018, the occurrence of HIV was reported as 38 million and the recorded deaths was around 7 million. Further, it was also recorded that around 23.3 million people out of the 37.9 million people were undergoing antiretroviral therapy. To suppress the HIV virus and stop its progression, antiretroviral drugs are more effective. This drug also prevents the onward transmission of HIV infection. In the early stages of the infection the drug has proven to show reductions in rates of death and infections when use is made of a potent ARV regimen. The WHO recommends ART for all people with HIV as soon as possible after diagnosis without any restrictions of CD4 counts.
The antiretroviral drugs market is anticipated to grow with a CAGR of around 6% over the forecast period, i.e. 2020-2028 owing to decreasing cost of healthcare treatment, improving rate of diagnosis, increasing awareness of HIV treatment and growing medical spending. The antiretroviral drugs market is segmented by drug type and by region. Based on drug type, the market is bifurcated into protease inhibitors, integrase inhibitors, multi-class combination products, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and others, out of which, multi-class combination products is predicated to hold largest and dominant market share in this anti-retroviral drugs market owing to the better clinical outcome and replacing the conventional treatment method which involve multiple tablets. The increasing sale of this multi class combination tablets, are expected to give the fuel to the growth of this segment in the global antiretroviral drugs market. CLICK TO DOWNLOAD SAMPLE REPORT
Rising Investments and Funding to Drive the Market Growth
Increasing investment and funding in the healthcare industry has boosted the number of research and development activities related to anti-retroviral drug which in turn is increasing the growth of this market.
Covid-19 to Drive the Market Growth
Manufacturers of antiretroviral drugs have increased to meet the demand for medicines in the wake of corona virus outbreak. Antiretroviral-- lopinavir, ritonavir which are used in combination to treat HIV, have proved effective against it. This drug blocks the ability of HIV infection to bind with healthy cells and stops them to reproduce further.
Growing Portfolio to inhibit the Market Growth
Increasing portfolio of generic antiretroviral drug is expected to inhibit the market growth. As many companies majorly work on generic version of the antiretroviral drugs, launching them at cheaper costs and adoption of generic antiretroviral drug is very high, which is anticipated to restrict the market growth.
Our in-depth analysis of the antiretroviral drugs market includes the following segments:
By Drug Type
- Protease Inhibitors
- Integrase Inhibitors
- Multi-class Combination Products
- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Based on regions, the antiretroviral drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
North America region hold the largest share of this market on the back of high ART coverage rate and increasing emphasis on given branded drugs. On the other hand, growing R&D activity in this region is fueling the market growth. In Latin America and Europe is anticipated to hold the second largest share in this market during the forecast period owing to the increasing number of HIV cases. Presently, the highest growth is observed in Asia Pacific on account of increasing cases among people of this region, especially in India.
The antiretroviral drugs market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Top Featured Companies Dominating the Market
- Johnson and Johnson
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Gilead Sciences Inc.
- Abbott Laboratories
- AstraZeneca plc
- Merck & Co.
- Roche Holding AG
- Novartis international AG